A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B‐cell lymphoma-Reference-Cited by-同舟云学术

A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B‐cell lymphoma

Published:2021-06-04 Issue:7 Volume:112 Page:2845-2854
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Terui Yasuhito¹,Rai Shinya²^ORCID,Izutsu Koji³^ORCID,Yamaguchi Motoko⁴,Takizawa Jun⁵,Kuroda Junya⁶,Ishikawa Takayuki⁷,Kato Koji⁸^ORCID,Suehiro Youko⁹,Fukuhara Noriko¹⁰,Ohmine Ken¹¹,Goto Hideki¹²,Yamamoto Kazuhito¹³,Kanemura Nobuhiro¹⁴,Ueda Yasunori¹⁵,Ishizawa Kenichi¹⁶,Kumagai Kyoya¹⁷,Kawasaki Atsuko¹⁸,Saito Tomohisa¹⁸,Hashizume Misato¹⁸,Shibayama Hirohiko¹⁹

Affiliation:

1. Department of Hematology and Oncology The Cancer Institute Hospital of the Japanese Foundation for Cancer Research Tokyo Japan

2. Department of Hematology and Rheumatology Kindai University Hospital Osaka Japan

3. Department of Hematology National Cancer Center Hospital Tokyo Japan

4. Department of Hematology and Oncology Mie University Graduate School of Medicine Mie Japan

5. Department of Hematology, Endocrinology and Metabolism Faculty of Medicine Niigata University Niigata Japan

6. Division of Hematology and Oncology Kyoto Prefectural University of Medicine Kyoto Japan

7. Department of Hematology Kobe City Medical Center General Hospital Kobe Japan

8. Department of Medicine and Biosystemic Science Kyushu University Graduate School of Medical Sciences Fukuoka Japan

9. Department of Hematology Kyushu Cancer Center Fukuoka Japan

10. Department of Hematology and Rheumatology Tohoku University Hospital Miyagi Japan

11. Department of Hematology Jichi Medical University Hospital Tochigi Japan

12. Department of Hematology Faculty of Medicine and Graduate School of Medicine Hokkaido University Sapporo Japan

13. Department of Hematology and Cell Therapy Aichi Cancer Center Hospital Aichi Japan

14. First Department of Internal Medicine Gifu University Hospital Gifu Japan

15. Department of Hematology Kurashiki Central Hospital Okayama Japan

16. Department of Third Internal Medicine Yamagata University Hospital Yamagata Japan

17. Department of Hematology and Medical Oncology Chiba Cancer Center Chiba Japan

18. Chugai Pharmaceutical Co Ltd, Tokyo Japan

19. Department of Hematology and Oncology Osaka University Hospital Osaka Japan

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.14937

Reference28 articles.

1. Orphanet.Diffuse large B‐cell lymphoma 2020. Available fromhttps://www.orpha.net/consor/cgi‐bin/OC_Exp.php?lng=en&Expert=544. Accessed January 14 2021.

2. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

3. StewartBW WildCP.World Cancer Report 2014. Available fromhttp://publications.iarc.fr/Non‐Series‐Publications/World‐Cancer‐Reports/World‐Cancer‐Report‐2014. Accessed January 14 2021.

4. A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma

5. Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Analysis of histologic, immunohistochemical and genomic features of large B cell lymphoma tumors may predict response to polatuzumab vedotin based therapy in patients with relapsed/refractory disease;Clinical Lymphoma Myeloma and Leukemia;2024-09

2. Update of antibody–drug conjugates for hematological malignancies;Current Opinion in Oncology;2024-06-28

3. A real-world pharmacovigilance study of polatuzumab vedotin based on the FDA adverse event reporting system (FAERS);Frontiers in Pharmacology;2024-06-25

4. Aligning outcomes: DLBCL prognosis at a 4th Level University Hospital in Bogotá is comparable to high-income nations, identification of additional prognostic markers for overall survival and relapse;ecancermedicalscience;2024-06-20

5. A real-world pharmacovigilance analysis of the FDA adverse event reporting system events for polatuzumab vedotin;Expert Opinion on Drug Safety;2024-05-02